FATE
Fate Therapeutics Inc
Clinical-stage biopharmaceutical company developing iPSC-derived cellular immunotherapies for cancer and immune disorders
CUSIP: 31189P102HealthcareUS1 holder
Total Value
$130.35M
Total Shares
2.20M
Net Share Change
+450.0K
Activity
1 buying
Investor
Value
Shares
Weight
Change
Lone Pine Capital
$130.35M2.20M shares
ADD+450.0K(+25.7%)